Related Experiment Video
Updated: Jun 12, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice
Jing Liu1, Ming-Wei Wang, Ping Gu
1The First Hospital of Hebei Medical University, Brain Aging and Cognitive Neuroscience Laboratory of Hebei Province, Shijiazhuang, China.
Abstract:
Senescence-accelerated mouse prone 8 (SAMP8) has an early onset of senility and a shorter life span, providing with cognitive impairment. Contrasted with C57BL/6 mouse, which is most commonly used in the study of Parkinson's disease (PD), SAMP8 needs shorter period of breeding and might be good candidate for the investigation of cognitive impairment in PD. Studies had shown the increase of sensibility to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) with aging in C57BL/6 mouse. However, the sensitivity of MPTP neurotoxicity depends on the strains of animal and the exact mechanisms of the progression of PD promoted by aging is lack of consensus. Here, we showed after MPTP injection, the spontaneous activity of both young (3-month-old) and old (6-month-old) SAMP8 decreased dramatically, and the old mice required longer recovery time. Immunohistochemical and immunoblot analysis revealed that old mice displayed significant reductions in the dopaminergic neuron numbers and tyrosine hydroxylase (TH) protein. Microglia protein (CD11b) in the striatum of old mice increased more pronouncedly than that in the young mice from 24 h to 3 days. Inducible nitric oxide synthase (iNOS) in the striatum remarkably increased, however, no discernible difference between the two groups was found. These results suggested that the sensibility to MPTP increased with aging in SAMP8. A greater increase of microglial activation in old mice may be a possible mechanism to explain how advancing age predisposes the dopamine system to parkinsonism. The MPTP-SAMP8 model will start a new consideration for the study of PD.
Insights
The senescence-accelerated mouse prone 8 (SAMP8) model shows increased sensitivity to MPTP neurotoxicity with aging. Enhanced microglial activation in older SAMP8 mice may explain age-related predisposition to Parkinson
Area of Science:
- Neuroscience
- Aging Research
- Pharmacology
Background:
- Senescence-accelerated mouse prone 8 (SAMP8) exhibits premature aging and cognitive deficits.
- The C57BL/6 mouse is standard for Parkinson's disease (PD) research, but SAMP8 offers a shorter breeding cycle.
- Aging increases susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in C57BL/6 mice, yet mechanisms remain debated.
Purpose of the Study:
- To investigate the MPTP neurotoxicity sensitivity in young versus aged SAMP8 mice.
- To explore the role of aging and microglial activation in MPTP-induced dopaminergic neurodegeneration within the SAMP8 model.
Main Methods:
- MPTP was administered to young (3-month-old) and old (6-month-old) SAMP8 mice.
- Spontaneous activity levels and recovery times were monitored.
- Immunohistochemical and immunoblot analyses assessed dopaminergic neuron numbers, tyrosine hydroxylase (TH), CD11b (microglia), and inducible nitric oxide synthase (iNOS) expression in the striatum.
Main Results:
- MPTP injection significantly reduced spontaneous activity in both young and old SAMP8 mice, with older mice showing longer recovery.
- Aged SAMP8 mice exhibited marked reductions in dopaminergic neuron count and TH protein levels compared to young mice.
- Microglial activation (CD11b) was significantly more pronounced in aged mice post-MPTP exposure.
Conclusions:
- Aging increases susceptibility to MPTP neurotoxicity in the SAMP8 mouse model.
- Enhanced microglial activation in aged SAMP8 mice is a potential mechanism underlying age-related vulnerability in the dopamine system.
- The MPTP-treated SAMP8 model presents a valuable new platform for studying Parkinson's disease and cognitive impairment associated with aging.
